Stunning timing... Epic!The S&P Biotech ETF is now up 37% in less than 2 months and about 5% from its high for the year. It is on fire. Stunning timing. Gilles has potentially picked off the AEZS assets right at the bottom of the market in a legendary manner. AEZS has been ~100% higher in the last year compared to where it is trading right now.
C$50 million cash, C$113 million in tax loss carryforwards, a diagnostic cashcow about to be partnered with its most important market potentially approved in 2024, a pipeline of other assets(eg. AIM Biologicals).
Stunning timiing...
He called it:
"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels." news release